格隆汇7月30日丨交大昂立（维权）(600530.SH)公布2025年半年度报告，报告期实现营业收入1.51亿 元，同比下降5.77%；归属于上市公司股东的净利润224.86万元，同比下降30.54%；基本每股收益 0.0029元。 ...

广发证券股份有限公司 关于威海百合生物技术股份有限公司差异化权益分派 事项的核查意见 广发证券股份有限公司（以下简称"广发证券"或"保荐人"）作为威海百 合生物技术股份有限公司（以下简称"百合股份"、"上市公司"或"公司"）首 次公开发行股票的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券 交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股 份》《上海证券交易所上市公司自律监管指南第 2 号—业务办理》等相关法律法 规的要求，对百合股份差异化权益分派事项进行了审慎核查，具体情况如下： 《上海证券交易所 上市公司自律监管指引第 7 号—回购股份》等相关法律法规、规范性文件和《公 司章程》的相关规定，公司已回购股份不参与利润分配。基于以上情况，造成公 司本次权益分派实施时股权登记日的总股本与实际参与分配的股份总数存在差 异。因此，公司 2024 年度利润分配实施差异化分红。 二、股东会审议通过的差异化权益分派的方案及调配现金分红总额 公司于2025年6月6日召开了2024年年度股东大会，审议通过了《关于公司 净利润139,309,114.98元，截 至2024年12 月31日，公司 ...

Core Insights - The health supplement market in China has become one of the largest globally, with significant growth potential remaining in the trillion-yuan market [1] - The online health supplement market is projected to exceed 120 billion by 2025, with an overall growth rate of 15% [2] - The consumer demographic is evolving, with a notable shift towards a "dumbbell-shaped" structure, where older adults and new middle-class consumers are driving demand [10] Market Overview - China's health supplement market is large and growing rapidly, with a projected market size of 399.8 billion in 2024, reflecting a 3% year-on-year growth [1] - By 2030, the market size is expected to surpass 1.5 trillion, maintaining a high compound annual growth rate [1] E-commerce Trends - E-commerce platforms are crucial channels for the health supplement industry, showing heightened growth trends [2] - Interest e-commerce is outpacing traditional shelf e-commerce, achieving over 20% annual growth [2] Product Development - The health supplement efficacy landscape is evolving, with traditional categories like bone health and immunity remaining strong, while new categories like moisture removal and emotional health are emerging [2][4] - Innovative product forms such as micro-bubbles and unique capsules are gaining traction, enhancing consumer experience beyond traditional forms [4] Pricing Dynamics - The average daily price of health supplements is around 10 yuan, with most efficacy products priced below 6 yuan, while categories like weight management and anti-aging command higher prices [6] - New products are achieving a premium price point, with an average daily price of 15.8 yuan compared to 8.7 yuan for older products, indicating a trend towards premiumization [8] New Product Strategy - 58% of existing brands are focusing on new product launches, averaging 4 new SKUs per brand annually, highlighting the importance of innovation in brand strategy [8] - New products account for 54% of the market by quantity, although they currently represent only 24% of sales, indicating growth potential [8] Consumer Demographics - The consumer base is shifting, with older adults (60+) contributing significantly to the market, transitioning from basic health to chronic disease prevention and management [10] - The new middle-class demographic (ages 25-45) is emerging as a core growth driver, shifting their focus from "curing" to "preventing" health issues [10]

面对这场在数字暗流中出现的"坑老骗老"新变种，对传统监管手段提出了更严峻挑战，也对新思维、新 战法提出了新要求。例如作为责任主体，网络平台应扎紧"篱笆"，抖音、微信、企业微信等作为重要的 私域流量入口，必须升级技术手段，加强对异常群组的识别与监控；电商平台、小程序服务商则需对涉 及老年人健康产品的直播间内容进行更严格的前置审核与动态巡查，对"养生讲堂""健康咨询"等敏感名 称的直播间提高警惕，建立快速下架和封停机制。 市场监管、网信、公安等部门也必须深化协同，建立针对涉老网络欺诈的专项情报共享与联合执法机 制。要提升电子证据固定与分析能力，应对骗子的"快闪"战术。对于查实的案件，不仅要重罚涉事商 家，更要顺藤摸瓜，追究为其提供技术支持和支付通道的"帮凶"责任，打掉整个黑色产业链。同时，要 畅通和优化针对老年人的网络举报渠道，如开发更简便的一键举报功能，支持语音举报等。 作为老年人的"反诈防火墙"，子女晚辈需承担起"数字反哺"的责任，主动帮助父母识别网络风险，耐心 解释常见骗术，提醒他们警惕任何线上"热情"的健康推销。社区、老年大学、公益组织应常态化开展形 式新颖、通俗易懂的"银发族"数字素养与防骗知识普及活动 ...

Core Insights - The increasing prevalence of electronic devices has heightened awareness of the potential visual hazards associated with prolonged screen exposure, leading to a surge in demand for lutein as a vital nutrient for eye health [1][3] - The children's market for lutein products has become a competitive battleground, driven by rising concerns among parents regarding children's vision health [1][15] Market Overview - The domestic market for lutein is estimated to reach nearly 6 billion yuan, with a compound annual growth rate (CAGR) of 19.8% from 2020 to 2024, significantly outpacing global market growth [4][3] - The eye care sector is the primary contributor to market growth, with annual sales of lutein soft capsules exceeding 200 million bottles [4] Competitive Landscape - The lutein market is characterized by intense competition across both health food and regular food sectors, with no dominant brand currently leading the market [2][20] - Major players in the extraction and processing segment include Chenguang Biotech, DSM, and Kemin, creating a "three-legged" competitive structure [4] Product Development - The market has seen a rapid increase in the registration of lutein health products, with over 150 products registered, primarily in capsule form [7][8] - Innovative product forms such as gummies and ready-to-drink beverages are gaining popularity, with the market for lutein gummies expected to exceed 1.5 billion yuan by 2024 [11] Consumer Trends - The demand for lutein products is driven by the rising incidence of myopia among children, with the overall myopia rate in Chinese children reaching 51.9% [18] - The average price of imported lutein products is significantly higher than that of domestic products, with imported items often exceeding 100 yuan per unit [17] Regulatory Environment - Lutein products are primarily classified as health foods and must undergo a registration process, as they are not included in the approved health food ingredient directory [9][14] - The lack of a clear definition for dietary supplements in China has led to many imported lutein products being marketed as regular foods, despite their health claims [13] Future Outlook - The lutein market is expected to continue evolving, with a focus on product differentiation and innovation to address the challenges of market saturation and consumer trust [20][22] - Companies are encouraged to invest in research and development to create unique products that can withstand competition and avoid the pitfalls of market homogenization [22]

Group 1: Health Impacts of High Temperatures - Extreme heat poses significant health risks, including heatstroke and accelerated aging processes in humans [1] - High temperatures induce oxidative stress, disrupt protein homeostasis, activate inflammatory pathways, and directly age skin and organs [1][3] - Chronic inflammation triggered by high temperatures can silently damage various body tissues [3] Group 2: Antioxidant Properties of Astaxanthin - Astaxanthin, a potent antioxidant, can penetrate cell membranes and effectively neutralize free radicals throughout the body [3] - It inhibits the production and release of inflammatory factors such as IL-6 and TNF-α, providing a balanced anti-inflammatory effect [3][5] - Astaxanthin offers protective benefits against UV-induced skin damage, reducing the penetration and harm caused by UVA and UVB rays [5] Group 3: Industry Leadership and Product Development - Green A Bio is a leading player in the astaxanthin industry, having developed proprietary technologies that break the technological monopoly held by the US and Japan [7] - The company has launched innovative products, including the "Red A Aista" and the anti-aging astaxanthin series, which combine natural astaxanthin with GABA and collagen peptides [7] - The growing medical research on astaxanthin suggests expanding applications in anti-aging and disease prevention, positioning it as a key health supplement [7]

Investment Rating - The industry investment rating is "Positive" [8] Core Insights - Ruby oil (Calanus oil) is gaining attention in the health supplement industry due to its rich content of beneficial components such as polyunsaturated fatty acids and astaxanthin, which possess anti-inflammatory properties. The total market size for the fish oil sector in China is projected to reach approximately 5.6 billion yuan in 2024, with a CAGR of 10% from 2010 to 2024. The demand is driven by both the aging population and a growing trend among younger consumers seeking anti-inflammatory benefits [2][5][19]. Summary by Sections Ruby Oil Overview - Ruby oil is exclusively produced by the Norwegian company Zooca Calanus and is derived from Calanus finmarchicus, a type of copepod found in non-industrial waters of Norway. Its composition includes 38% polyunsaturated fatty acids, 15% monounsaturated fatty acids, 24% polyunsaturated fatty acids, 16% saturated fatty acids, and 2% astaxanthin. The oil is primarily targeted at oral anti-inflammatory and anti-aging markets, particularly within the broader fish oil market [4][16]. Market Trends - The demand for anti-inflammatory products is increasing across all age groups. The market for oral anti-inflammatory and anti-aging products in China reached 57.4 billion yuan in 2023, with a CAGR of 18% from 2016 to 2023. The fish oil and omega-3 products market is expected to grow to 5.6 billion yuan by 2024, with a CAGR of 10% from 2010 to 2024 [5][19]. Product Distribution and Target Demographics - Ruby oil products are primarily sold through cross-border e-commerce platforms, focusing on female consumers. Major brands utilizing ruby oil include VitaOcean, Feicui, and SuperSmart, with prices ranging from 328 yuan to 502 yuan for 60 capsules. Marketing strategies are increasingly targeting younger demographics, despite the traditional focus on older consumers [6][23].

证券代码：300791 证券简称：仙乐健康 公告编码：2025-073 债券代码：123113 债券简称：仙乐转债 仙乐健康科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 收盘价低于当期转股价格的 85%，即 27.10 元/股，预计后续触发转股价格向下修 正条件。若触发，公司将于触发当日召开董事会审议决定是否修正转股价格，并 及时履行信息披露义务。 一、可转债发行上市的基本情况 （一）可转换公司债券发行概况 经中国证券监督管理委员会《关于同意仙乐健康科技股份有限公司向不特定 对象发行可转换公司债券注册的批复》（证监许可〔2021〕927 号）同意注册， 仙乐健康科技股份有限公司（以下简称"仙乐健康"或"公司"）向不特定对象 发行可转换公司债券 1,024.89 万张，每张面值 100.00 元，募集资金总额为人民 币 102,489.29 万元，扣除相关发行费用后实际募集资金净额为人民币 101,616.75 万元。本次向不特定对象发行的可转换公司债券向公司在股权登记日收市后登记 在册的原股东优先配售，原股东优先配售后余额部分（ ...

Core Viewpoint - The "Weight Management Year" initiative is driving a national trend towards weight loss in response to the rising obesity rates among adults in China, which presents a significant market opportunity in the health sector [4][7]. Group 1: Obesity Statistics and Health Implications - Over half of Chinese adults are overweight or obese, with adult overweight rates at 34.3% and obesity rates at 16.4% as of 2018. Projections suggest that by 2030, these rates could rise to 70.5% and 31.8% respectively without intervention [4]. - Obesity is a major risk factor for chronic diseases such as hypertension, diabetes, and cardiovascular diseases, leading to increased healthcare costs and reduced quality of life for millions [4]. Group 2: Market Growth in Health and Fitness - The health market in China is rapidly expanding, with the organic food market reaching over 100 billion yuan in 2023. The light food market is expected to exceed 200 billion yuan by 2025, and the meal replacement market could surpass 350 billion yuan by 2027 [5]. - The sports industry in China generated a total output of 36,741 billion yuan in 2023, with a value-added contribution of 14,915 billion yuan, accounting for 1.15% of GDP [5]. Group 3: Fitness and Weight Management Industry - There are over 1.575 million fitness-related enterprises in China, indicating a vibrant market landscape. The weight loss drug and health supplement markets are also experiencing rapid growth, with projections suggesting the weight loss drug market could exceed 14.9 billion dollars by 2030 [6]. - The demand for professional weight management and health management personnel is high, providing new career opportunities in the industry [6]. Group 4: Overall Impact of the Initiative - The "Weight Management Year" initiative is not only raising public health awareness but also creating a new wave of opportunities and growth in the health industry, valued at trillions [7].

Core Insights - NYO3's Ageless anti-aging series has officially entered the Hema APP, with its popular product, the beauty pill, leading the launch [1] - The product quickly topped the "Tmall International Oral Beauty List" in its first month and is the only designated nutritional product for the China-Norway air route [1] Group 1: Quality Consensus - Hema is known for its stringent quality standards for brands, requiring product safety, reliable supply chains, and strong market reputation [3] - NYO3 has been in the Chinese market for seven years, focusing on quality to build its presence, using Antarctic krill oil and adhering to Norwegian production standards [3] - NYO3 has achieved a leading market position in global krill oil sales for two consecutive years and has passed ORIVO inspections for five years, achieving 100% defect-free status [3] Group 2: Precise Fit - The Ageless beauty pill targets Hema's core young consumer base, particularly women aged 25 and above, who seek high-quality products [4][6] - The product contains 14 premium ingredients and boasts a nutrient absorption rate of 98%, utilizing a unique phospholipid cell-level delivery technology [4] - The product's formulation is based on Nobel Prize-winning "biological rhythm" theory, offering a time-specific intake approach to meet the anti-aging needs of young women [4] Group 3: Mutual Empowerment - The entry of NYO3's Ageless into Hema represents a strategic choice for both the brand and the channel, aiming for "second growth" [7] - NYO3 aims to leverage Hema's high-end user base and data insights to solidify its position as the leading Nordic anti-aging brand in China [7] - Hema's introduction of high-end brands like NYO3 Ageless enhances its premium oral beauty product category and aligns with its positioning for new middle-class consumers [7]